$TBPH
Theravance Biopharma Inc Stock $tbph

$tbph Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000155837023002595 Filed on March 01, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$10.42M	$14.65M	$51.35M
YoY Change	-21.06%	-1.99%	-7.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$19.18M	$15.97M	$67.07M
YoY Change	0.32%	-59.17%	-32.45%
% of Gross Profit
Research & Development	$14.57M	$14.70M	$63.39M
YoY Change	-37.33%	-52.92%	-67.27%
% of Gross Profit
Depreciation & Amortization	$625.0K	$659.0K	$2.600M
YoY Change	-45.22%	-51.58%	-25.71%
% of Gross Profit
Operating Expenses	$35.33M	$32.08M	$143.3M
YoY Change	-31.66%	-54.89%	-54.23%
Operating Profit	-$24.91M	-$17.43M	-$91.96M
YoY Change	-35.3%	-68.96%	-64.33%
Interest Expense	$550.0K	$3.172M	$6.369M
YoY Change	-95.28%	-86.77%	-86.42%
% of Operating Profit
Other Income/Expense, Net	$2.979M		$8.545M
YoY Change	-894.4%		670.51%
Pretax Income	-$22.48M	-$14.26M	-$92.82M
YoY Change	-11.56%	-55.7%	-53.49%
Income Tax	-$395.0K	-$3.000K	$9.000K
% Of Pretax Income
Net Earnings	-$22.09M	-$10.36M	$872.1M
YoY Change	-14.87%	-67.65%	-537.32%
Net Earnings / Revenue	-212.04%	-70.74%	1698.54%
Basic Earnings Per Share	-$0.35	-$0.15	$11.85
Diluted Earnings Per Share	-$0.35	-$0.15	$11.85
COMMON SHARES
Basic Shares Outstanding	62.86M	67.37M	73.59M
Diluted Shares Outstanding	62.93M		73.59M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$241.3M	$327.5M	$327.5M
YoY Change	63.55%	88.79%	88.79%
Cash & Equivalents	$187.7M	$298.2M	$298.2M
Short-Term Investments	$53.60M	$29.31M	$29.31M
Other Short-Term Assets	$7.805M	$9.195M	$9.195M
YoY Change	-15.93%	-51.11%	-51.11%
Inventory
Prepaid Expenses
Receivables	$12.27M	$16.79M	$16.79M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$261.3M	$353.5M	$353.5M
YoY Change	27.71%	41.46%	41.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.10M	$11.88M	$52.00M
YoY Change	-8.56%	-13.05%	-2.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$18.78M	$0.00	$0.00
YoY Change	-80.05%	-100.0%	-100.0%
Other Assets	$12.09M	$6.899M	$201.9M
YoY Change	278.62%	113.72%	4867.65%
Total Long-Term Assets	$277.2M	$253.9M	$253.9M
YoY Change	83.92%	103.23%	103.23%
TOTAL ASSETS
Total Short-Term Assets	$261.3M	$353.5M	$353.5M
Total Long-Term Assets	$277.2M	$253.9M	$253.9M
Total Assets	$538.6M	$607.4M	$607.4M
YoY Change	51.55%	62.05%	62.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.663M	$1.554M	$1.554M
YoY Change	76.36%	-49.84%	-49.84%
Accrued Expenses	$23.50M	$27.14M	$27.14M
YoY Change	-30.03%	-29.42%	-29.42%
Deferred Revenue	$24.00K	$24.00K
YoY Change	-75.51%	-75.51%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$26.18M	$28.72M	$28.72M
YoY Change	-40.76%	-50.99%	-50.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$7.678M	$1.657M	$136.9M
YoY Change	216.23%	-31.53%	147.04%
Total Long-Term Liabilities	$7.678M	$1.657M	$136.9M
YoY Change	216.23%	-31.53%	-79.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.18M	$28.72M	$28.72M
Total Long-Term Liabilities	$7.678M	$1.657M	$136.9M
Total Liabilities	$33.86M	$30.37M	$165.6M
YoY Change	-27.38%	-50.22%	-76.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$876.0M	-$853.9M
YoY Change	-50.0%	-50.53%
Common Stock	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$370.6M	$441.8M	$441.8M
YoY Change
Total Liabilities & Shareholders Equity	$538.6M	$607.4M	$607.4M
YoY Change	51.55%	62.05%	62.05%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$22.09M	-$10.36M	$872.1M
YoY Change	-14.87%	-67.65%	-537.32%
Depreciation, Depletion And Amortization	$625.0K	$659.0K	$2.600M
YoY Change	-45.22%	-51.58%	-25.71%
Cash From Operating Activities	-$11.22M	-$124.1M	-$187.0M
YoY Change	-56.96%	192.35%	-10.04%
INVESTING ACTIVITIES
Capital Expenditures	$938.0K	$266.0K	$572.0K
YoY Change	-475.2%	-159.91%	-116.79%
Acquisitions
YoY Change
Other Investing Activities	-$42.11M	$39.43M	$1.155B
YoY Change	-230.88%	249.9%	802.72%
Cash From Investing Activities	-$43.05M	$39.16M	$1.154B
YoY Change	-234.84%	261.8%	826.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$128.8M
YoY Change			19.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-56.24M	-35.47M	-758.8M
YoY Change	3783.98%	-23906.71%	-926.05%
NET CHANGE
Cash From Operating Activities	-11.22M	-124.1M	-187.0M
Cash From Investing Activities	-43.05M	39.16M	1.154B
Cash From Financing Activities	-56.24M	-35.47M	-758.8M
Net Change In Cash	-110.5M	-120.4M	208.2M
YoY Change	-2607.53%	282.59%	2350.71%
FREE CASH FLOW
Cash From Operating Activities	-$11.22M	-$124.1M	-$187.0M
Capital Expenditures	$938.0K	$266.0K	$572.0K
Free Cash Flow	-$12.16M	-$124.3M	-$187.6M
YoY Change	-52.91%	196.07%	-8.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.06
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001583107
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	tbph	Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture	-57000
CY2020	tbph	Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture	-463000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-47000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-98000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	8000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-39000
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	2709000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3989000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3786000
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3344000
CY2021	tbph	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	1863000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.87
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.46
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	836000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	837000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74435000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	833000
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q3	tbph	Sublease Monthly Base Rent SubleaseMonthlyBaseRent	100000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74435000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65227000
CY2022	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal Statement Of Income Extensible List DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense
CY2022Q4	tbph	Fair Value Assets Level2 To Level1 Transfer Amount FairValueAssetsLevel2ToLevel1TransferAmount	0
CY2021Q3	us-gaap	Lessee Operating Sublease Option To Extend LesseeOperatingSubleaseOptionToExtend	false
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
CY2022Q4	tbph	Unrecognized Tax Benefits Total UnrecognizedTaxBenefitsTotal	64200000
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36033
CY2022	dei	Entity Registrant Name EntityRegistrantName	THERAVANCE BIOPHARMA, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	KY
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1226628
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	P.O. Box 309
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ugland House, South Church Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	George Town, Grand Cayman
CY2022	dei	Entity Address Country EntityAddressCountry	KY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	KY1-1104
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	808-6000
CY2022	dei	Security12b Title Security12bTitle	Ordinary Share $0.00001 Par Value
CY2022	dei	Trading Symbol TradingSymbol	TBPH
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	677000000.0
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62864474
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	San Mateo, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	298172000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89959000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29312000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	83506000
CY2021Q3	tbph	Sublease Percentage Of Increase In Annual Base Rent SubleasePercentageOfIncreaseInAnnualBaseRent	0.03
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2180000
CY2022Q4	tbph	Receivables From Collaboration Partners ReceivablesFromCollaborationPartners	16785000
CY2021Q4	tbph	Receivables From Collaboration Partners ReceivablesFromCollaborationPartners	14065000
CY2022Q4	tbph	Prepaid Clinical And Development Services PrepaidClinicalAndDevelopmentServices	1513000
CY2021Q4	tbph	Prepaid Clinical And Development Services PrepaidClinicalAndDevelopmentServices	10245000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7682000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8561000
CY2021Q4	tbph	Due From Related Parties Discontinued Operation DueFromRelatedPartiesDiscontinuedOperation	43534000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	353464000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	249870000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11875000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13657000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40126000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39690000
CY2022Q4	tbph	Future Contingent Milestone And Royalty Assets FutureContingentMilestoneAndRoyaltyAssets	194200000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	836000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	837000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6899000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3228000
CY2021Q4	tbph	Equity Method Investment Discontinued Operations EquityMethodInvestmentDiscontinuedOperations	67537000
CY2022Q4	us-gaap	Assets Assets	607400000
CY2021Q4	us-gaap	Assets Assets	374819000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1554000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3098000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10314000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12796000
CY2022Q4	tbph	Accrued Clinical And Development Expenses Current AccruedClinicalAndDevelopmentExpensesCurrent	4932000
CY2021Q4	tbph	Accrued Clinical And Development Expenses Current AccruedClinicalAndDevelopmentExpensesCurrent	17010000
CY2022Q4	tbph	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	4020000
CY2021Q4	tbph	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	2898000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6753000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	503000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	24000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	98000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1118000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1304000
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1246000
CY2021Q4	tbph	Non Recourse Debt Current Discontinued Operations NonRecourseDebtCurrentDiscontinuedOperations	16940000
CY2021Q4	tbph	Accrued Interest Payable Discontinued Operations Current AccruedInterestPayableDiscontinuedOperationsCurrent	2694000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28715000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	58587000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45407000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52681000
CY2022Q4	tbph	Future Royalty Payment Contingencies FutureRoyaltyPaymentContingencies	25438000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	192000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	310000
CY2022Q4	tbph	Unrecognized Tax Benefits Total UnrecognizedTaxBenefitsTotal	64191000
CY2021Q4	tbph	Unrecognized Tax Benefits Total UnrecognizedTaxBenefitsTotal	240000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1657000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	228035000
CY2021Q4	tbph	Non Recourse Debt Due2035 Noncurrent NonRecourseDebtDue2035Noncurrent	371359000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	230000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	230000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65227000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1295725000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1387469000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-853911000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1726043000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	441800000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-338573000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	607400000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	374819000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51346000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55311000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71857000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63392000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	193657000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	260953000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	67073000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	99296000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	108531000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	12838000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	20142000
CY2022	us-gaap	Operating Expenses OperatingExpenses	143303000
CY2021	us-gaap	Operating Expenses OperatingExpenses	313095000
CY2020	us-gaap	Operating Expenses OperatingExpenses	369484000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-91957000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-257784000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-297627000
CY2022	us-gaap	Interest Expense InterestExpense	6369000
CY2021	us-gaap	Interest Expense InterestExpense	8547000
CY2020	us-gaap	Interest Expense InterestExpense	8547000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3034000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8545000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1109000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2831000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92815000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-265222000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-303343000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-151000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8520000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-92824000
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-265071000
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-294823000
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	1143930000
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	65645000
CY2020	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	16806000
CY2022	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	178974000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	964956000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	65645000
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	16806000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.26
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.26
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.82
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.82
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-4.73
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-4.73
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	13.11
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	13.11
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.95
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.95
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.27
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.27
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.85
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	11.85
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.87
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.87
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.46
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.46
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73591000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73591000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69461000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69461000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62345000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62345000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39734000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62061000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62976000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-15000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	872117000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-199473000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-278115000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-223840000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	139915000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3701000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	62976000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1361000
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	9749000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-98000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-303751000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-303751000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	108180000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3466000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	62061000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	9061000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-47000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-338573000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-338573000
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	128830000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	802000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39734000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3450000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-15000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	441800000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	964956000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	65645000
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	16806000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-92824000
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-265071000
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-294823000
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	3716000
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	4802000
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	4707000
CY2022	tbph	Amortization And Accretion Income AmortizationAndAccretionIncome	681000
CY2021	tbph	Amortization And Accretion Income AmortizationAndAccretionIncome	-10000
CY2020	tbph	Amortization And Accretion Income AmortizationAndAccretionIncome	1079000
CY2022	tbph	Interest Accretion On Future Royalty Payment Contingencies InterestAccretionOnFutureRoyaltyPaymentContingencies	974000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	39734000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	62061000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	62976000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3034000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-10000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	95000
CY2022	tbph	Increase Decrease In Receivables From Collaboration Partners IncreaseDecreaseInReceivablesFromCollaborationPartners	2720000
CY2021	tbph	Increase Decrease In Receivables From Collaboration Partners IncreaseDecreaseInReceivablesFromCollaborationPartners	-1803000
CY2020	tbph	Increase Decrease In Receivables From Collaboration Partners IncreaseDecreaseInReceivablesFromCollaborationPartners	-6128000
CY2022	tbph	Increase Decrease In Prepaid Clinical And Development Services IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices	-8733000
CY2021	tbph	Increase Decrease In Prepaid Clinical And Development Services IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices	-10129000
CY2020	tbph	Increase Decrease In Prepaid Clinical And Development Services IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices	17638000
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	704000
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-2867000
CY2020	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	2327000
CY2022	tbph	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-4424000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3802000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	972000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1110000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1612000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3534000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3658000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-14086000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-37225000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5983000
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1246000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-192000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11463000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-26465000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1024000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1742000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1600000
CY2022	tbph	Period Increase Decrease Unrecognized Tax Benefits PeriodIncreaseDecreaseUnrecognizedTaxBenefits	63952000
CY2021	tbph	Period Increase Decrease Unrecognized Tax Benefits PeriodIncreaseDecreaseUnrecognizedTaxBenefits	-189000
CY2020	tbph	Period Increase Decrease Unrecognized Tax Benefits PeriodIncreaseDecreaseUnrecognizedTaxBenefits	-8542000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-525000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	777000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	936000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2425000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-235775000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-262747000
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-184566000
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	27917000
CY2020	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	12344000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-186991000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-207858000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-250403000
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	572000
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3406000
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	6616000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	103145000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	158305000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	401987000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	158000000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	286199000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	399318000
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	17000
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	19942000
CY2022	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	2709000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1866000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	64000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	58875000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	124494000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	10721000
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	1095134000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1154009000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	124494000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10721000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	128830000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	108180000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	139915000
CY2022	tbph	Proceeds From Funding For Royalty Rights ProceedsFromFundingForRoyaltyRights	24464000
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	380000000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	802000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3466000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3701000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1361000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3450000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9061000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9749000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-738617000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	91860000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	279881000
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-20189000
CY2020	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-16796000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-758806000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	91860000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	263085000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	208212000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8496000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23403000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90796000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82300000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58897000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299008000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90796000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82300000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	22244000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	39029000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	24024000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	117966000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-4089000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosures in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299008000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company invests in a variety of financial instruments and, based on its policy, limits the amount of credit exposure with any one issuer, industry or geographic area for investments other than instruments backed by the US federal government. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s future contingent milestone and royalty assets and receivables primarily relate to amounts due under its collaboration and other agreements. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies or specific to its collaboration agreements. The Company performs periodic evaluations of its customers and generally does not require collateral. For the year ended December 31, 2022, 2021, and 2020, the Company did not experience any material losses related to its receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p>
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90796000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82300000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	8000000.0
CY2021	us-gaap	Advertising Expense AdvertisingExpense	9300000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	6300000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	900000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	76000000.0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	75000000.0
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-92824000
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-265071000
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-294823000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	964956000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	65645000
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	16806000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	872132000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-199426000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-278017000
CY2022	tbph	Weighted Average Number Of Shares Outstanding Before Forfeitures WeightedAverageNumberOfSharesOutstandingBeforeForfeitures	73591000
CY2021	tbph	Weighted Average Number Of Shares Outstanding Before Forfeitures WeightedAverageNumberOfSharesOutstandingBeforeForfeitures	69518000
CY2020	tbph	Weighted Average Number Of Shares Outstanding Before Forfeitures WeightedAverageNumberOfSharesOutstandingBeforeForfeitures	62808000
CY2021	tbph	Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture	-57000
CY2020	tbph	Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture	-463000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73591000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69461000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62345000
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.26
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.82
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-4.73
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	13.11
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.95
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.27
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.85
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5487000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14145000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13229000
CY2022	tbph	Profit Loss Percentage As Per Collaboration Agreement ProfitLossPercentageAsPerCollaborationAgreement	0.35
CY2022	tbph	Collaboration Arrangement Upfront Payments Receivable CollaborationArrangementUpfrontPaymentsReceivable	205000000.0
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	900000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	300000
CY2022	tbph	Collaborative Arrangement Research And Development Expenses Reimbursed To Entity CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity	6682000
CY2021	tbph	Collaborative Arrangement Research And Development Expenses Reimbursed To Entity CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity	7891000
CY2020	tbph	Collaborative Arrangement Research And Development Expenses Reimbursed To Entity CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity	10078000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51346000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55311000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71857000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	298172000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89959000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81467000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	303557000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	27000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	303542000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	133738000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	133734000
CY2022	tbph	Marketable Securities Maximum Contractual Maturity Period MarketableSecuritiesMaximumContractualMaturityPeriod	P3M
CY2022	tbph	Marketable Securities Average Contractual Maturity Period MarketableSecuritiesAverageContractualMaturityPeriod	P1M
CY2022Q4	tbph	Fair Value Assets Level1 To Level2 Transfer Amount FairValueAssetsLevel1ToLevel2TransferAmount	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	37279000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	27000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	37279000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	27000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	35017000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	35017000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	5000
CY2022Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	19900000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44711000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52149000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32836000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	38492000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11875000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13657000
CY2022	us-gaap	Depreciation Depreciation	2600000
CY2021	us-gaap	Depreciation Depreciation	3500000
CY2020	us-gaap	Depreciation Depreciation	3300000
CY2022Q4	tbph	Area Of Leased Space AreaOfLeasedSpace	162000
CY2022	tbph	Number Of Building Leased NumberOfBuildingLeased	2
CY2021Q4	tbph	Tenant Improvement Allowance TenantImprovementAllowance	10200000
CY2021Q3	tbph	Area Of Property Subleased AreaOfPropertySubleased	21000
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	13100000
CY2021Q3	tbph	Premium Over Proportionate Lease Payment Obligations PremiumOverProportionateLeasePaymentObligations	4200000
CY2021Q3	tbph	Percentage Of Excess Sublease Payments Received Shared With Lessor PercentageOfExcessSubleasePaymentsReceivedSharedWithLessor	0.50
CY2021Q3	tbph	Premium Over Proportionate Lease Payment Obligations Shared With Lessor PremiumOverProportionateLeasePaymentObligationsSharedWithLessor	2100000
CY2021Q3	tbph	Percentage Of Excess Sublease Payments Received Retained PercentageOfExcessSubleasePaymentsReceivedRetained	0.50
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40126000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39690000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6753000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	503000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45407000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52681000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52160000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	53184000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8314000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7625000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	8732000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	9312000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	8971000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9947000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10623000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10828000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11145000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	11479000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	28576000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	82598000
CY2022Q4	tbph	Tenant Improvement Allowance TenantImprovementAllowance	8912000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	21526000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52160000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0863
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	616334000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	4859000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	7475000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	7475000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	536000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1072000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1072000
CY2022	tbph	Interest Accretion On Future Royalty Payment Contingencies InterestAccretionOnFutureRoyaltyPaymentContingencies	974000
CY2022	us-gaap	Interest Expense InterestExpense	6369000
CY2021	us-gaap	Interest Expense InterestExpense	8547000
CY2020	us-gaap	Interest Expense InterestExpense	8547000
CY2014Q2	tbph	Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans	3
CY2021	tbph	Share Based Compensation Allocation Of Recognized Period Costs Capitalized Reversed Amount ShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedReversedAmount	2800000
CY2021	tbph	Share Based Compensation Allocation Of Recognized Period Costs Capitalized Reversed Amount ShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedReversedAmount	2800000
CY2022	tbph	Share Based Compensation Allocation Of Recognized Period Costs Capitalized Reversed Amount ShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedReversedAmount	800000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	1700000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39734000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62061000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62976000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39734000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62061000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	62976000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	43403000
CY2022	tbph	Income Loss Before Income Taxes Noncontrolling Interest IncomeLossBeforeIncomeTaxesNoncontrollingInterest	-92815000
CY2021	tbph	Income Loss Before Income Taxes Noncontrolling Interest IncomeLossBeforeIncomeTaxesNoncontrollingInterest	-265222000
CY2020	tbph	Income Loss Before Income Taxes Noncontrolling Interest IncomeLossBeforeIncomeTaxesNoncontrollingInterest	-303343000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-151000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-8520000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-151000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8520000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0001
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0006
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0281
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8500000
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-179000000.0
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2022Q4	tbph	Uncertain Tax Benefits UncertainTaxBenefits	76000000.0
CY2022Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	0
CY2022Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	104236000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	115606000
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	19409000
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	19409000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	16176000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	28372000
CY2022Q4	tbph	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	283260000
CY2021Q4	tbph	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	287177000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4298000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10432000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1795000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3590000
CY2022Q4	tbph	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	11239000
CY2021Q4	tbph	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	11607000
CY2022Q4	tbph	Deferred Tax Assets Prepaid Expenses DeferredTaxAssetsPrepaidExpenses	304000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	30000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10505000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	440747000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	486698000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	422325000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	477868000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	18422000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8830000
CY2022Q4	tbph	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	8634000
CY2021Q4	tbph	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	8575000
CY2022Q4	tbph	Deferred Tax Liabilities Future Contingent Milestone And Royalty Assets DeferredTaxLiabilitiesFutureContingentMilestoneAndRoyaltyAssets	11725000
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	255000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	20359000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8830000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1937000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	477900000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	422300000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	63447000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	395000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	11971000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	75023000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	7395000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	8371000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	75999000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	76000000.0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	75000000.0
CY2021Q2	us-gaap	Share Price SharePrice	15.00
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7705000
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	115600000
CY2021Q3	tbph	Percentage Of Reduction In Workforce PercentageOfReductionInWorkforce	0.75
CY2022	us-gaap	Restructuring Charges RestructuringCharges	12800000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	20100000
CY2022Q3	us-gaap	Restructuring Charges RestructuringCharges	33000000.0
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	9550000
CY2022	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	6074000
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	15624000
CY2022Q4	tbph	Guarantees And Indemnifications Liability GuaranteesAndIndemnificationsLiability	0
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	12.35
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.06
CY2022Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	250000000.0
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13196000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11050000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12451000
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14649000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	51698000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	37929000
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	21595000
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	32081000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-38502000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26879000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9144000
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-17432000
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-41538000
CY2022Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-26570000
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10460000
CY2022Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-14256000
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	15592000
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	18379000
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	927091000
CY2022Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3894000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25946000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8191000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	916631000
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-10362000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.55
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.55
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.35
CY2022Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.35
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.21
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.21
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.21
CY2022Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.21
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.21
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.21
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.24
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.24
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	12.35
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	12.14
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	12.14
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14257000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12914000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13194000
CY2021Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14946000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	98149000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	77024000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	66809000
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	71113000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-83892000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-64110000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-53615000
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-56167000
CY2021Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-86490000
CY2021Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-64856000
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-55910000
CY2021Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-57814000
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	6811000
CY2021Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	12451000
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	20602000
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	25780000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-79679000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-52405000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-35308000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-32034000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.35
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.35
CY2021Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.99
CY2021Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.99
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.76
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.76
CY2021Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.78
CY2021Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.78
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.11
CY2021Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.11
CY2021Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.19
CY2021Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.19
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.28
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.28
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.35
CY2021Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.35
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2022	tbph	Profit Loss Percentage As Per Collaboration Agreement ProfitLossPercentageAsPerCollaborationAgreement	0.35

Files In Submission

Name	View Source	Status
0001558370-23-002595-index-headers.html	Edgar Link	pending
0001558370-23-002595-index.html	Edgar Link	pending
0001558370-23-002595.txt	Edgar Link	pending
0001558370-23-002595-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tbph-20221231.xsd	Edgar Link	pending
tbph-20221231x10k.htm	Edgar Link	pending
tbph-20221231x10k006.jpg	Edgar Link	pending
tbph-20221231x10k007.jpg	Edgar Link	pending
tbph-20221231x10k008.jpg	Edgar Link	pending
tbph-20221231x10k009.jpg	Edgar Link	pending
tbph-20221231x10k010.jpg	Edgar Link	pending
tbph-20221231x10k012.jpg	Edgar Link	pending
tbph-20221231xex10d72.htm	Edgar Link	pending
tbph-20221231xex10d77.htm	Edgar Link	pending
tbph-20221231xex21d1.htm	Edgar Link	pending
tbph-20221231xex23d1.htm	Edgar Link	pending
tbph-20221231xex23d2.htm	Edgar Link	pending
tbph-20221231xex31d1.htm	Edgar Link	pending
tbph-20221231xex31d2.htm	Edgar Link	pending
tbph-20221231xex32.htm	Edgar Link	pending
tbph-20221231_cal.xml	Edgar Link	unprocessable
tbph-20221231_def.xml	Edgar Link	unprocessable
tbph-20221231_lab.xml	Edgar Link	unprocessable
tbph-20221231_pre.xml	Edgar Link	unprocessable
tbph-20221231x10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TBPH
Theravance Biopharma Inc Stock $tbph

2023 Q1 Form 10-K Financial Statement

#000155837023002595 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TBPH Theravance Biopharma Inc Stock $tbph

2023 Q1 Form 10-K Financial Statement

#000155837023002595 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TBPH
Theravance Biopharma Inc Stock $tbph